Skip to main content

Drug Interactions between ibritumomab and Stimufend

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pegfilgrastim ibritumomab tiuxetan

Applies to: Stimufend (pegfilgrastim) and ibritumomab

ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with radiolabeled ibritumomab tiuxetan have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while radiopharmaceuticals like yttrium-90 and indium-111 radiolabeled ibritumomab tiuxetan primarily target rapidly dividing cells.

MANAGEMENT: Some authorities recommend that patients not receive hematopoietic growth factors for 3 weeks prior to administration of radiolabeled ibritumomab tiuxetan and for 2 weeks following completion of the treatment in order to assess for adequate bone marrow reserve correctly and also because of the potential sensitivity of rapidly dividing myeloid cells to radiation.

References (2)
  1. "Product Information. In-111 Zevalin (ibritumomab tiuxetan)." IDEC Pharmaceuticals Corporation
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer